DOCSLIB.ORG

Tilray: Global Leader

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Tilray: Global Leader Tilray: Global Leader What Is Medical Cannabis? Medical cannabis is produced using the flowers of the cannabis plant. Cannabis contains over a hundred different types of cannabinoids, two of the most dominant and common are THC and CBD. Depending on how cannabis plants are cultivated and processed, cannabis products can have a range of potencies of THC and CBD. Patients use medical cannabis to treat or alleviate symptoms for a number of conditions. THC: Some of the reported pharmacodynamic effects of THC-dominant medical cannabis include: Analgesic, muscle relaxant, anti-emetic, appetite stimulating, psychoactive effects, Immunomodulant, anti-seizure, anti-inflammatory and more. CBD: The reported pharmacodynamic effects of CBD-dominant medical cannabis include: Analgesic, muscle relaxant, anxiolytic, neuroprotective, anti- oxidant, anti-psychotic activity, anti-seizure, anti-inflammatory and more. Precisely-Formulated Products Tilray is working closely with patients, physicians, and regulators to provide consistent availability of a range of pharmaceutical-grade medical cannabis products, in accordance with regulations where we operate. We believe patients choose Tilray because we are a scientifically rigorous brand known for producing pure, precise and predictable medical-grade products. We take a scientific approach to product development. Our product line focuses on active ingredients and standardized, well-defined preparations. We use formulations and delivery formats that are intended to allow for consistent and measured dosing, and we test all our products for potency and purity. • Whole flower cannabis: Tilray cultivates more than 50 strains to meet patient needs in THC-dominant, CBD-dominant or balanced varieties. • Ground flower cannabis: Milled cannabis in THC-dominant, CBD-dominant or balanced varities. • Full-Spectrum Oil: Tilray Oils are produced in THC-dominant, CBD-dominant or balanced varieties. The oil can be used in a dropper or taken as a capsule. • Purified Oils: Tilray Purified Oils and capsules undergo a state-of-the-art cold extraction process designed to preserve cannabinoid and terpene content, delivering a pure, aromatic and effective pharmaceutical-grade product. • Clinical Compounds: Tilray is proud to partner with world-leading hospitals and universities to develop and produce precisely crafted study drugs to study the efficacy of medical cannabis for a variety of conditions. We work with established pharmaceutical distributors and pharmacy suppliers to sell our products around the world. 1 Advancing Cannabinoid Science and Fostering Mainstream Acceptance State-Of-The-Art Production Process Tilray choreographs a complex series of cutting-edge processes to deliver unparalleled product to its patients. From cultivation to shipping, Tilray’s team brings precision, professionalism and care to each stage of the process. Advancing Clinical Research Tilray is committed to advancing scientific understanding of the therapeutic potential and risks of cannabinoid-based medicines by collaborating with researchers to conduct clinical trials at world-renowned hospitals and universities. Tilray has supported ten different clinical trials to-date: 1. University of Sydney, NSW Government, Chris O’Brien Lifehouse Testing the efficacy and tolerability of medical cannabis as treatment for chemotherapy induced nausea & vomiting. 2. The Hospital for Sick Children, Toronto, Canada Testing the efficacy and tolerability of medical cannabis oil as treatment for pediatric epilepsy/dravet syndrome. 3. University of British Columbia, Canada Testing medical cannabis as treatment for post-traumatic stress disorder. 4. Grupo Español de Investigación en Neuroocología GEINO, Spain Testing medical cannabis to treat glioblastoma. 5. UCSD, San Diego, USA Testing the efficacy and tolerability of medical cannabis (capsule) as treatment for Essential Tremor. 6. Murdoch Children’s Research Institute, Melbourne, Australia Evaluating the feasibility and acceptability of a randomized placebo- controlled trial of the efficacy of cannabidiol (CBD) in reducing Severe Behavioral Problems in children with intellectual Disabilities. 7. McGill University Health Centre Testing medical cannabis on immune activation in people living with HIV. 8. NYU School of Medicine Trial testing CBD treatment for patients suffering from Alcohol Use Disorder. 9. NYU School of Medicine Trial testing CBD treatment for patients suffering from AUD comorbid with Post-Traumatic Stress Disorder (PTSD). 10. Columbia University First-of-its-kind trial testing the efficacy of cannabis as a treatment for taxane-induced peripheral neuropathy, which affects 67% of women undergoing breast cancer treatment. 2 Leading, Legitimizing and Defining the Future of Cannabis We Are A Global Pioneer We have supplied high-quality medical cannabis products to tens of thousands of patients in fourteen countries spanning five continents across the globe through our subsidiaries in Australia, Canada, Germany and Latin America, and through agreements with established pharmaceutical distributors. Tilray was founded in 2013 with the belief that patients and consumers should have safe access and a reliable supply of quality- tested pure, precise and predictable cannabis products. We aspire to lead, legitimize and define the future of our industry by building the world’s most trusted and valued cannabis company. We are pioneering the future of medical cannabis research, cultivation, processing and distribution globally. Tilray’s EU campus in Cantanhede serves as a hub to support Tilray’s clinical research, product developments and distribution across Europe and other international markets. What Sets Us Apart: • Among the first companies to be licensed by Health Canada to cultivate and sell cannabis in Canada. • The first company to legally export medical cannabis from North America to four continents. • The first cannabis company to successfully complete an Initial Public Offering (IPO) on a major U.S. stock exchange. • Among the first company to cultivate in two countries – Portugal and Canada. • Our Tilray Nanaimo, Canada and Cantanhede, Portugal facilities are Good Manufacturing Practices (GMP) certified. GMP is an internationally recognized standard that ensures medicines are consistently produced and controlled with the highest levels of pharmaceutical grade quality and purity. GMP-certified has allowed us to export our products all over the world. through our subsidiaries in Australia, Canada, Germany and Latin America, and through agreements with established pharmaceutical distributors. 3 International Expansion Seizing Global Opportunities Tilray Portugal In July 2017, the Portuguese National Authority of Medicines and Health Products (IN-FARMED) awarded Tilray a license to cultivate, import and export bulk medical cannabis. Tilray received its first phase of Good Manufacturing Practices certification in August 2019 and approval for manufacturing license GMP certification in December 2019, which allows us to manufacture and distribute finished medical cannabis products throughout the EU and other international markets. The EU requires adherence to GMP standards for the manufacture of active substances and medicinal products, including cannabis products. Tilray has established sales and distribution arrangements to distribute GMP- produced medical cannabis through major pharmaceutical distribution channels throughout Germany and the European Union. Tilray has also formed a global alliance with Sandoz AG, a worldwide leader in generic pharmaceuticals and biosimilars and a part of Novartis group, to increase availability of high quality medical cannabis products around the world in jurisdictions where regulations permit. Tilray Portugal: By The Numbers • 2.5mSQFT multi-faceted production facility that includes outdoor and greenhouse cultivation sites, research labs, processing, packaging and distribution sites for medical cannabis and cannabinoid-derived medical products. • Over 200 employees. This number is expected to grow in 2020. • €20m invested in the build-out of our operations at our EU campus to-date. 4.
Load more

Recommended publications
  • Pioneering the Future of Global Cannabis June 2020
    Pioneering the Future of Global Cannabis June 2020 ©2020 TILRAY Disclaimer Investors and prospective investors should rely only on the information contained in the continuous expected; that adverse changes or developments affecting the Company’s main or planned facilities may Although management has attempted to identify important risk factors that could cause actual results to disclosure filings (the “Filings”) of Tilray Inc. (the “Company”). This presentation is qualified in its entirety have an adverse effect on the Company; that the medical cannabis industry and market may not continue differ materially from those contained in the forward-looking information in this presentation, there may by reference to, and must be read in conjunction with, the information contained in the Filings. An investor to exist or develop as anticipated or the Company may not be able to succeed in this market; that the be other risk factors not presently known to the Company or that the Company presently believes are not or prospective investor is not entitled to rely on parts of the information contained in this presentation to Company has a limited operating history and a history of net losses and that it may not achieve or maintain material that could also cause actual results or future events to differ materially from those expressed in the exclusion of others, and the Company is not authorized to provide different or additional information. profitability in the future; risks related to the Company’s current or proposed international operations; risks such forward-looking information in this presentation. There can be no assurance that such information Unless otherwise specified, all monetary amounts in this presentation are in United States dollars.
    [Show full text]
  • Tilray Inc - Class 2 Annual Report 2021
    Tilray Inc - Class 2 Annual Report 2021 Form 10-K (NASDAQ:TLRY) Published: July 28th, 2021 PDF generated by stocklight.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38594 TILRAY, INC. (Exact name of Registrant as specified in its Charter) Delaware 82-4310622 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 655 Madison Avenue, Suite 1900 New York, NY 10065 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: ( 844) 845-7291 Securities registered pursuant to Section 12(b) of the Act: Trading Title of each class Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share TLRY The Nasdaq Stock Market LLC The Nasdaq Global Select Market Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES ☒ NO ☐ Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YES ☐ NO ☒ Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Tilray Annual Report 2020
    Tilray Annual Report 2020 Form 10-K (NASDAQ:TLRY) Published: March 2nd, 2020 PDF generated by stocklight.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38594 TILRAY, INC. (Exact name of Registrant as specified in its Charter) Delaware 82-4310622 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 1100 Maughan Road Nanaimo, BC V9X IJ2 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: ( 844) 845-7291 Securities registered pursuant to Section 12(b) of the Act: Trading Title of each class Symbol(s) Name of each exchange on which registered Class 2 Common Stock, $0.0001 par value per share TLRY The Nasdaq Stock Market LLC The Nasdaq Global Select Market Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES ☒ NO ☐ Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YES ☐ NO ☒ Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Vote for the Business Combination of Aphria And
    VOTE FOR THE BUSINESS COMBINATION OF APHRIA AND TILRAY TO CREATE THE LARGEST GLOBAL CANNABIS COMPANY March 12, 2021 Dear Aphria Shareholders and Tilray Stockholders: We are excited to invite you to attend the special meeting of shareholders (the ‘‘Aphria Meeting’’) of Aphria Inc. (‘‘Aphria’’) and the special meeting of the stockholders (the ‘‘Tilray Meeting’’) of Tilray, Inc. (‘‘Tilray’’), to approve the proposed business combination between the two companies (the ‘‘Transaction’’). The Aphria Meeting will take place via live audio webcast at www.virtualshareholdermeeting.com/APHA2021 on April 14, 2021 at 4:00 pm (Eastern time) and the Tilray Meeting will take place via live audio webcast at www.virtualshareholdermeeting.com/TLRY2021SM, on April 16, 2021 at 11:00 a.m. (Eastern time). YOUR VOTE IS IMPORTANT. Whether or not you expect to attend the Aphria Meeting or the Tilray Meeting virtually, please submit your vote as soon as possible. We urge you to read the enclosed materials carefully and to promptly vote by following the instructions in the enclosed materials. We thank you for your consideration and continued support. Sincerely, Irwin D. Simon Brendan Kennedy Chief Executive Officer and Chair of the President, Chief Executive Officer, and Chair of Board of Directors of Aphria Inc. the Board of Directors of Tilray, Inc. EXECUTIVE SUMMARY TRANSACTION DETAILS The transaction (the ‘‘Transaction’’) is to be completed pursuant to an arrangement (the ‘‘Arrangement’’) under the Business Corporations Act (Ontario). Under the terms of the Arrangement, shareholders of Aphria will receive 0.8381 of a share of Tilray common stock for each Aphria share held.
    [Show full text]
  • Tilray & Aphria Announce Closing of Transaction That Creates the “New
    Tilray & Aphria Announce Closing of Transaction That Creates the “New” Tilray – a Global Cannabis Leader May 3, 2021 Operational Efficiencies Expected to Generate Approximately US$81 Million Annual Pre-Tax Cost-Saving Synergies for New Tilray Within Eighteen Months Irwin D. Simon, Aphria’s Chairman and CEO, will Lead the New Tilray and Has Appointed New Executive Leadership Team; New Members of the Board of Directors Also Appointed New Tilray Poised to Transform the Global Cannabis Industry as a Consumer Packaged Goods Powerhouse with a Diversified Portfolio of Leading Brands Renewed Financial Strength to Drive Accelerated Growth Strategy and Sustained Profitability Tilray’s Shares Will Continue Trading on the NASDAQ Under Symbol “TLRY”; Starting May 5, 2021, Tilray’s Shares Will Commence Trading on the Toronto Stock Exchange Under Symbol “TLRY” NEW YORK & LEAMINGTON, Ontario--(BUSINESS WIRE)--May 3, 2021-- Tilray, Inc. (“Tilray”) and Aphria Inc. (“Aphria”) today announced the completion of the previously announced business combination, ushering in a new era in the global cannabis industry. The combined company, which will operate as Tilray (the “Company”), brings together two highly complementary businesses to create the leading cannabis-focused consumer packaged goods (“CPG”) company with the largest global geographic footprint in the industry . The combined company had a market cap of approximately US$8.2 billion based on the closing stock prices on April 30, 2021. The Company’s class 2 common stock (“Tilray Shares”) will continue to trade on the Nasdaq Global Select Exchange under the ticker symbol “TLRY” and will commence trading on the Toronto Stock Exchange under the ticker symbol “TLRY” on May 5, 2021.
    [Show full text]
  • Growing Hemp for Grain Lamont County 2020 Outline • Hemp Food Industry Overview • Market Trends • Quality • Agronomy • Economics
    Growing Hemp for Grain Lamont County 2020 Outline • Hemp Food Industry Overview • Market trends • Quality • Agronomy • Economics Fresh Hemp Foods – A Tale of Two Companies Hemp Oil Canada Facility, Ste. Agathe, MB Multiple Uses A Broad Array of Products for Multiple Needs Hemp in the Marketplace Cereal/ Granola Snacks Bulk Section Frozen Non Dairy Bev Sports Nutrition Hemp Distribution 2019 – Tilray Inc. Purchases Fresh Hemp Foods • Presence in 12 countries, 5 continents • 3 Divisions • Medical Cannabis • Adult Recreational Cannabis • Health Foods and Natural Health Products Market Trends News From CHTA – 2019 Exports • 18,639 tonnes • $112 Million (16% increase) • 33 countries • USA ($102M), S.Korea ($1.6M), Netherlands ($1.4M) • Net Exports: $109 Million (15% increase) USA Trends • 2018 Farm Bill – legalizes hemp * Includes greenhouse Agronomics Farm Operations • Contract acres • Agronomic advice • Seed Genetics • Quality • Seed cleaner audits • Logistics and transportation • Grower payment • Research & Development of Best Management Practices Licensing • Controlled by Health Canada • Certified seed only • Low THC • All growers licensed • GPS coordinates required • Subject to inspection A good hemp crop starts with a proper seed bed Seeding ▪ 28 to 30 pounds per acre ▪ 100 to 125 seedlings per m2 ▪ Seed shallow (1-2 cm) ▪ Warm soil ▪ Pack to ensure soil contact ▪ Similar management to canola ▪ Seed costs ▪ Fertility Fertility - Organic Weed Management: Inter-row cultivation Canopy Closure – competitive exclusion Disease • Few diseases
    [Show full text]
  • Dear Aphria Shareholders, Vote for the Business Combination of Aphria and Tilray to Create the Ote Largest Global Cannabis Company
    IMPORTANT NOTICE Dear Aphria Shareholders, vote FOR the business combination of Aphria and Tilray to create the ote largest global cannabis company. STRATEGIC RATIONALE Aphria’s Board of Directors unanimously recommends that shareholders vote FOR the transaction. The Board firmly believes that, at this stage of development and expansion of the global cannabis market, those companies with financial strength and leading geographic scale, product range and brand expertise are most likely to succeed in the long-term. Further, the Boards of Directors of both companies believe that the combination of Aphria and Tilray is expected to unlock significant shareholder value as follows: To meet demand, the combined company will The combination of Aphria and Tilray will create the have state-of-the-art cultivation, processing and world’s largest global cannabis company with pro forma manufacturing facilities, as well as a complete revenue of US$685 million (C$874 million)1. portfolio of branded cannabis 2.0 products to strengthen its leadership position in Canada. In the United States, the combined company will have a strong consumer packaged goods presence and In the event of federal permissibility in the United infrastructure with two strategic pillars, including States, the combined company expects to be well- SweetWater Brewing Company, LLC, a leading cannabis positioned to compete in the U.S. cannabis market lifestyle branded craft brewer, and Manitoba Harvest given its existing strong brands and distribution system USA, LLC, a pioneer in branded hemp, CBD and in addition to its track record of growth in consumer- wellness products with access to 17,000 stores in North packaged goods and cannabis products.
    [Show full text]
  • Legalized Medical Cannabis
    LeadershipLeadership Team team Management Ehud Barak Alex Rabinovitch Amos Cohen Rami Levy Moshe Gavrilov Chairman CEO CFO COO CMO Former Prime Minister of Israel More than 20 years of business Former CFO at Trendline (TREN.TA) 20+ years of lead management 18-year career at Teva and M&A experience, spanning and VP of Finance at Walla from and operational experience Pharmaceuticals in executive 36-year career in the IDF, having various domestic and international Bezeq group, the largest Israeli at Netafim, the largest Israeli sales and marketing positions served as General Commander leader and operating roles communications company aggrotech company, expanding where he established distribution global operations development channels in emerging markets to more than 190 territories Medical Advisory Board (select members) Subversive Capital SUBVERSIVE CAPITAL SUBVERSIVE CAPITAL Prof. Zvi Bentwich Prof. Eitan Friedman Michael Auerbach Leland Hensch MD, PhD MD, PhD Founder Director Professor of Microbiology, Immunology Director and founder of the Suzanne Founder of Subversive Capital, General Partner of CFO and Director of Subversive’s SVX SPAC and and Genetics, and head of the Center Levy - Gertner Oncogenetics Unit, Subversive’s venture platform, Chairman and CEO of SVX General Partner of Subversive Capital Opportunity Fund for Emerging Tropical Diseases and Sheba Medical Center AIDS, at Ben Gurion University Previously, a seed investor in Privateer Former Goldman Sachs Equity Partner Holdings and Tilray board member based in New York and London
    [Show full text]
  • In the Court of Chancery of the State of Delaware in Re
    IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE TILRAY, INC. Consolidated REORGANIZATION LITIGATION C.A. No. 2020-0137-KSJM MEMORANDUM OPINION Date Submitted: February 5, 2021 Date Decided: June 1, 2021 Peter B. Andrews, Craig J. Springer, Jessica Zeldin, David M. Sborz, ANDREWS & SPRINGER LLC, Wilmington, DE; Gregory V. Varallo, BERNSTEIN LITOWITZ BERGER & GROSSMANN LLP, Wilmington, DE; Jeffrey M. Gorris, Christopher M. Foulds, FRIEDLANDER & GORRIS, P.A., Wilmington, DE; Jeremy S. Friedman, David F.E. Tejtel, FRIEDMAN OSTER & TEJTEL PLLC, Bedford Hills, NY; Mark Lebovitch, David Wales, Andrew Blumberg, BERNSTEIN LITOWITZ BERGER & GROSSMAN LLP, New York, NY; D. Seamus Kaskela, KASKELA LAW LLC, Newtown Square, PA; Counsel for Plaintiffs. Michael A. Pittenger, Matthew F. Davis, David A. Seal, Caneel Radinson-Blasucci, POTTER ANDERSON & CORROON LLP, Wilmington, DE; Counsel for Nominal Defendant Tilray, Inc. Michael P. Kelly, Daniel M. Silver, Sarah E. Delia, MCCARTER & ENGLISH, LLP, Wilmington, DE; Counsel for Defendants Brendan Kennedy and Privateer Evolution, LLC. Carl N. Kunz, III, K. Tyler O’Connell, Albert J. Carroll, MORRIS JAMES LLP, Wilmington, DE; Ronald L. Berenstain, Sean C. Knowles, PERKINS COIE LLP, Seattle, WA; Counsel for Defendants Christian Groh and Michael Blue. Susan W. Waesco, John P. DiTomo, Daniel T. Menken, MORRIS, NICHOLS, ARSHT & TUNNELL LLP, Wilmington, DE; Counsel for Defendant Maryscott Greenwood. Blake Rohrbacher, Matthew W. Murphy, Elizabeth A. Heise, RICHARDS, LAYTON & FINGER, P.A., Wilmington, DE; Counsel for Defendant Michael Auerbach. McCORMICK, C. Bucking the advice of Keep Your Day Job, to “keep [your day job] on ice while you’re lining up your long shot,”1 three friends quit their jobs nearly a decade ago to capitalize on the expansion of the legal cannabis industry.
    [Show full text]
  • Tilray: Next in Line in a Budding Cannabis Industry Target Price of $45/Share
    Aug 15, 2018 Tilray: Next in line in a Budding Cannabis Industry Target Price of $45/share Today is a Turning Point in the Cannibas Inc.- Let the big money flow in On Jan 3, 2018, Citron predicted that Aurora Cannabis would fall from the then $14 to $6.50. It currently trades at $6.19. Today we state that you would have to be ‘high’ to short any of the marijuana names based on the recent investment by Constellation in to Canopy Growth, the largest investment in the space ($4bn). The premium paid to market shows confidence by Constellation that could rattle any short seller. The opportunity now lies in finding the next company to get a white knight at a premium to market and to Citron that answer is easy- Tilray. Citron believes that Tilray is best in class and if it were to get the same multiple we are assigning to Canopy, the stock would be trading at $45 a share. A potential seems imminent as less than two weeks ago, Tilray CEO Brendan Kennedy, stated in an analyst discussion on Reddit. “You’re already seeing Fortune 500 companies do deals in the space and I think you’ll see more as the year progresses. We may be a year or two away from an acquisition, but continue to believe it’s inevitable” --- Brendan Kennedy (CEO), early August 2018 Here are a few points why we believe Tilray will be the next ‘pot stock’ to go much “high[er]” • Best in Class Investors: Peter Thiel and Farallon Capital ($20bn fund) • Strategic Partnerships: The only cannabis company in bed with big pharma (Novartis).
    [Show full text]
  • Tilray Acquires Majority Position in Amended Medmen Convertible Notes
    Logo NEWS RELEASE Tilray Acquires Majority Position in Amended MedMen Convertible Notes 8/17/2021 Investment Provides Tilray a Potential Accelerated Path into U.S. Cannabis Market Upon Federal Legalization Amendment and Extension of Convertible Notes Enables MedMen to Reshape Balance Sheet and Further Accelerate its Growth Trajectory Tilray and MedMen CEOs to Host a Conference Call and Webcast at 5:00 PM Eastern Time NEW YORK & LOS ANGELES--(BUSINESS WIRE)-- Tilray, Inc. (“Tilray”) (Nasdaq l TSX: TLRY), a leading global cannabis- lifestyle and consumer packaged goods company, and MedMen Enterprises Inc. (“MedMen”) (CSE: MMEN) (OTCQX: MMNFF), a premier American cannabis retailer, today announced that Tilray has acquired the majority of the outstanding senior secured convertible notes (the “Notes”) of MedMen that were originally held by certain funds aliated with Gotham Green Partners, LLC and other funds (collectively, “GGP”). The acquisition provides Tilray with a path, subject to necessary regulatory approvals, to obtain a signicant equity position in MedMen through conversion of the Notes and exercise of associated warrants (the “Warrants”) following U.S. cannabis legalization (or Tilray’s waiver of such condition).In connection with the sale of the Notes, MedMen and GGP amended the restrictive covenants and extended the debt maturity to 2028 to provide MedMen the exibility to execute on its growth priorities and explore additional strategic opportunities. In addition, MedMen separately announced today a signicant equity investment from a private placement of MedMen Shares (as dened below) and warrants to a group of investors. MedMen is a leading cannabis retail brand in the U.S., holding 21 licenses and 25 retail locations across key urban centers, including the Bay Area, Los Angeles, Boston, Chicago, and Las Vegas, and a signicant position in California, the world’s largest market.
    [Show full text]
  • What Providers Should Know About Patients Using Cannabis Carol Freedman Rph, BCGP Objectives
    What Providers Should Know About Patients Using Cannabis Carol Freedman RPh, BCGP Objectives 1. Overview & understanding of cannabis products; availability and access 2. Awareness of potential drug interactions with cannabis 3. Evidence of Efficacy / Inefficacy 4. Discussion of “complementary alternative medicines” (CAM); cannabis use; documentation in medical chart 5. Talking points for patients using cannabis Pharmaceutical- vs Dispensary-Sourced Cannabinoids: What's the Difference? Authors: Daniel Friedman, MD, MSc; Anup D. Patel, MD Cannabis Background Cannabis = synonym for marijuana FDA Approved, Recreational (Adult-Use) & Medical Marijuana (MMJ) Federal: – Schedule I in the US – US federal law prohibits all possession, sale, and use of marijuana – Most parts of the cannabis plant and its derivatives (exception: Hemp derived CBD is legal < 0.3% THC) Massachusetts: – Cannabis Control and Advisory Board - ensures safe access to marijuana; may possess 1 oz./10 oz. at home Cannabis Plant Family 3 major species : – cannabis sativa (most common, highest level of THC) – cannabis indica (typically more CBD than THC) – cannabis ruderalis (few psychogenic properties) 3 major types of cannabinoinds; > 100 chemical entities: Plant (phytonacannabinoids) Synthetic Endogenous Phytonacannabinoids - therapeutic activity – THC (delta-9-tetrahydrocannabinol) psychotropic activity – CBD (cannabidiol) non-psychotropic activity – Terpenes – responsible for smell and taste of cannabis How Cannabis Works Endocannabinoid System (ECS) – Internal Homeostatic
    [Show full text]